Abstract
Background: The benzoxazepine JL13 is an analogue of the clozapine family of antipsychotic agents which target the 5-HT2A receptor, and has showed promise as an atypical antipsychotic agent. Based on the dearth of clinically effective anti-psychotic agents available, we sought to design and chemically synthesize additional analogues.
Methods: Structure function analysis was conducted using state of art computational methods, which were designed to highlight new candidates for chemical synthesis. Efficient syntheses were then conducted and the products screened for affinity to the receptor.
Results: Among many new analogues prepared, an aza analogue demonstrated seventeen times greater affinity for the receptor than JL13.
Conclusion: An efficient synthetic route to an aza-analogue of JL13 was developed and will allow rapid modifications of the core and synthesis of related libraries.
Keywords: 5HT receptor, antipsychotic, clozapine, diazepine, JL13, synthesis.
Central Nervous System Agents in Medicinal Chemistry
Title:Homology Modeling Inspired Synthesis of 5-HT2A Receptor Inhibitors: A Diazepine Analogue of the Atypical Antipsychotic JL13
Volume: 17 Issue: 3
Author(s): Enrico Mongeau, Gengyang Yuan, Zachary Minden, Scott Waldron, Raymond Booth, Daniel Felsing, Mary J. Ondrechen and Graham B. Jones*
Affiliation:
- Clinical and Translational Science Institute, Tufts University Medical Center, 800 Washington Street, Boston, MA 02111,United States
Keywords: 5HT receptor, antipsychotic, clozapine, diazepine, JL13, synthesis.
Abstract: Background: The benzoxazepine JL13 is an analogue of the clozapine family of antipsychotic agents which target the 5-HT2A receptor, and has showed promise as an atypical antipsychotic agent. Based on the dearth of clinically effective anti-psychotic agents available, we sought to design and chemically synthesize additional analogues.
Methods: Structure function analysis was conducted using state of art computational methods, which were designed to highlight new candidates for chemical synthesis. Efficient syntheses were then conducted and the products screened for affinity to the receptor.
Results: Among many new analogues prepared, an aza analogue demonstrated seventeen times greater affinity for the receptor than JL13.
Conclusion: An efficient synthetic route to an aza-analogue of JL13 was developed and will allow rapid modifications of the core and synthesis of related libraries.
Export Options
About this article
Cite this article as:
Mongeau Enrico , Yuan Gengyang , Minden Zachary , Waldron Scott, Booth Raymond , Felsing Daniel, Ondrechen J. Mary and Jones B. Graham*, Homology Modeling Inspired Synthesis of 5-HT2A Receptor Inhibitors: A Diazepine Analogue of the Atypical Antipsychotic JL13, Central Nervous System Agents in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1871524917666170426123607
DOI https://dx.doi.org/10.2174/1871524917666170426123607 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Nicotine and Gastrointestinal Disorders: Its Role in Ulceration and Cancer Development
Current Pharmaceutical Design Allosteric Modulation of Muscarinic Acetylcholine Receptors
Current Neuropharmacology Imaging of the Colon in Inflammatory Bowel Disease: Ready for Prime Time?
Current Drug Targets Long Term Caregiving: Helping Families of Persons with Mild Cognitive Impairment Cope
Current Alzheimer Research Huperzine A, A Potential Therapeutic Agent for Treatment of Alzheimers Disease
Current Medicinal Chemistry Feasibility of Delivering a Cognitive Behavioural Therapy-Based Resilience Curriculum to Young Mothers by Public Health Nurses
Adolescent Psychiatry Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research Mechanisms of Synaptic Homeostasis in Alzheimers Disease
Current Alzheimer Research Psychometric Comparison of Standard and Computerized Administration of the Alzheimers Disease Assessment Scale – Cognitive Subscale (ADASCog)
Current Alzheimer Research Vasculopathy in Hyperthyroid Rats and Targets for Drug Effects
Vascular Disease Prevention (Discontinued) Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Synthesis of 2, 3-Disubstituted-Quinazolin-4-(3H)-ones
Mini-Reviews in Medicinal Chemistry MicroRNA: A Multi-Facet Biological Target for Cancer and Other Diseases
Clinical Cancer Drugs Small Molecule Inhibitors of Stat3 Signaling Pathway
Current Cancer Drug Targets Ameliorative Effect of Trans-Sinapic Acid and its Protective Role in Cerebral Hypoxia in Aluminium Chloride Induced Dementia of Alzheimer's Type
CNS & Neurological Disorders - Drug Targets Appraisal of AβPP Transgenic Mice as Models for Alzheimers Disease Amyloid Cascade
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Current Challenges and Limitations in the Studies of Intrinsically Disordered Proteins in Neurodegenerative Diseases by Computer Simulations
Current Alzheimer Research The Effectiveness of Dimethyl Fumarate Monotherapy in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
Current Neuropharmacology Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design